ALK and non-small cell lung carcinoma: In addition, Sintilimab plus pemetrexed and platinum as the first-line treatment for patients with EGFR and ALK mutation-negative advanced or metastatic nonsquamous NSCLC was included in the National Medical Insurance Drug List in the China Medical Insurance Negotiations in December 2021.